Clinical data | |
---|---|
Trade names | Eybelis, Omlonti |
Other names | UR-7276, DE-117, Omidenepag isopropyl ( JAN JP) |
Routes of administration | Topical eye drops |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H28N6O4S |
Molar mass | 520.61 g·mol−1 |
3D model ( JSmol) | |
| |
|
Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension. [1] [3]
Omidenepag was approved for medical use in Japan in 2018, [3] and in the United States in September 2022. [2] [4]
Omidenepag is indicated for the treatment of glaucoma and ocular hypertension. [1] [3]
The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema. [3]
Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag. [5] Omidenepag is a selective prostaglandin E2 receptor agonist. [6] [7]
Omidenepag was developed by Ube Industries and Santen Pharmaceutical. [3]
Clinical data | |
---|---|
Trade names | Eybelis, Omlonti |
Other names | UR-7276, DE-117, Omidenepag isopropyl ( JAN JP) |
Routes of administration | Topical eye drops |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H28N6O4S |
Molar mass | 520.61 g·mol−1 |
3D model ( JSmol) | |
| |
|
Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension. [1] [3]
Omidenepag was approved for medical use in Japan in 2018, [3] and in the United States in September 2022. [2] [4]
Omidenepag is indicated for the treatment of glaucoma and ocular hypertension. [1] [3]
The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema. [3]
Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag. [5] Omidenepag is a selective prostaglandin E2 receptor agonist. [6] [7]
Omidenepag was developed by Ube Industries and Santen Pharmaceutical. [3]